Two shortcomings of nonviral gene therapy are a lack of tissue-specific targeting of vectors and low levels of gene transfer. Our laboratory has begun to address these limitations by designing ...
The use of in vivo electroporation (EP) as a therapeutic gene delivery approach has been successfully used in a variety of applications including cancer therapy and the regulation of protein levels to ...
Plasmid DNA lies at the heart of viral and mRNA vector production because it provides the coding sequences for gene-based advanced therapy medicinal products (ATMPs). Its manufacture is therefore ...
Processes yielding >500 mg plasmid DNA/L have previously been reported by Merck, Boehringer Ingelheim, and Nature Technology (NTC). Common features among these high-yield processes include the use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results